Shares of Opko Health, Inc. (NASDAQ:OPK) have earned a consensus rating of “Buy” from the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $14.72.
Several research analysts recently weighed in on the stock. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Jefferies Group LLC reaffirmed a “hold” rating and issued a $8.00 target price on shares of Opko Health in a report on Thursday, July 27th. Barrington Research boosted their price target on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 18th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $19.50 price target on shares of Opko Health in a research note on Tuesday, June 6th.
In other news, Vice Chairman Jane Ph D. Hsiao acquired 20,000 shares of Opko Health stock in a transaction that occurred on Thursday, May 11th. The shares were bought at an average cost of $6.93 per share, with a total value of $138,600.00. Following the transaction, the insider now directly owns 24,763,133 shares of the company’s stock, valued at approximately $171,608,511.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Phillip Md Et Al Frost acquired 1,125,000 shares of Opko Health stock in a transaction that occurred on Wednesday, May 10th. The stock was purchased at an average cost of $6.96 per share, for a total transaction of $7,830,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $21,359,898.96. The disclosure for this purchase can be found here. Insiders have bought a total of 2,756,000 shares of company stock worth $18,268,617 over the last 90 days. Corporate insiders own 40.19% of the company’s stock.
A number of hedge funds have recently bought and sold shares of OPK. Pacer Advisors Inc. raised its stake in Opko Health by 11.5% in the second quarter. Pacer Advisors Inc. now owns 66,638 shares of the biotechnology company’s stock worth $438,000 after buying an additional 6,858 shares during the period. Utah Retirement Systems raised its stake in Opko Health by 3.4% in the second quarter. Utah Retirement Systems now owns 60,600 shares of the biotechnology company’s stock worth $399,000 after buying an additional 2,000 shares during the period. BDO Wealth Advisors LLC purchased a new stake in Opko Health during the second quarter worth $399,000. Prudential Financial Inc. raised its stake in Opko Health by 6.1% in the second quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock worth $161,000 after buying an additional 1,400 shares during the period. Finally, Federated Investors Inc. PA purchased a new stake in Opko Health during the second quarter worth $201,000. 23.05% of the stock is currently owned by institutional investors.
Shares of Opko Health (OPK) traded down 0.63% during midday trading on Friday, hitting $6.28. The company had a trading volume of 1,848,397 shares. The stock has a 50 day moving average price of $6.48 and a 200 day moving average price of $7.40. The firm’s market capitalization is $3.51 billion. Opko Health has a 1-year low of $5.99 and a 1-year high of $12.15.
Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.02. The firm had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. The company’s quarterly revenue was up 1.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.02) EPS. On average, equities analysts anticipate that Opko Health will post ($0.20) EPS for the current fiscal year.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
